LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national firm specializing in shareholder rights litigation, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation (“Blueprint” or “the Company”) ( NASDAQ: BPMC) for violating securities laws.
The investigation aims to determine whether the Company has made false and/or misleading statements and/or has failed to disclose relevant information to investors. Blueprint announced top results from Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) on August 17, 2022. The company revealed that the absolute improvement in symptom score improved from 19.7 in the first part of the test at 15.6 in Part 2. Based on this news, shares of Blueprint fell 10% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us via the firm’s website at www.schallfirm.com or by email at bschall@schallfirm.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.
Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.
This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.
